Document Detail

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
MedLine Citation:
PMID:  16216934     Owner:  NLM     Status:  MEDLINE    
In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.
Elliot M Frohman; Olaf Stüve; Eva Havrdova; John Corboy; Anat Achiron; Robert Zivadinov; Per Soelberg Sorensen; J Theodore Phillips; Brian Weinshenker; Kathleen Hawker; Hans-Peter Hartung; Lawrence Steinman; Scott Zamvil; Bruce A C Cree; Stephen Hauser; Howard Weiner; Michael K Racke; Massimo Filippi
Related Documents :
17629614 - Multiple sclerosis and capgras' syndrome.
19752304 - Multiple sclerosis with predominant, severe cognitive impairment.
11254774 - Demyelinating disorder of the central nervous system occurring in black south africans.
9449474 - No increase of serum autoantibodies during therapy with recombinant human interferon-be...
24929574 - Endocrine encephalopathy.
20339034 - Circumferential pulmonary vein ablation with additional linear ablation results in an i...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Archives of neurology     Volume:  62     ISSN:  0003-9942     ISO Abbreviation:  Arch. Neurol.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-11     Completed Date:  2005-11-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372436     Medline TA:  Arch Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1519-30     Citation Subset:  AIM; IM    
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease Progression
Multiple Sclerosis / therapy*
Randomized Controlled Trials as Topic

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fish consumption and cognitive decline with age in a large community study.
Next Document:  Risk factors associated with beta-amyloid(1-42) immunotherapy in preimmunization gene expression pat...